Galectin Therapeutics (GALT) Gains from Investment Securities (2021 - 2026)
Galectin Therapeutics (GALT) posted quarterly Gains from Investment Securities of -$983000.0 for Q1 2026, down 4032.0% year-over-year from $25000.0 in Q1 2025, and down 546.82% quarter-over-quarter from $220000.0 in Q4 2025.
Powered by 
Analysis
Galectin Therapeutics (GALT) Gains from Investment Securities (2021 - 2026) Analysis & Trends
Galectin Therapeutics' Gains from Investment Securities history runs 6 years deep, the most recent figure standing at -$983000.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities fell 4032.0% year-over-year to -$983000.0; the TTM figure through Mar 2026 stood at $2.5 million (up 277.36% YoY), while the FY2025 annual figure was $3.5 million, up 703.06% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at -$983000.0, down from $220000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $2.2 million in Q3 2025, with the low at -$2.1 million in Q4 2024.
- The 5-year median for Gains from Investment Securities is $25000.0 (2025), against an average of $108823.5.
- The sharpest annual moves came in 2025 and 2026: Gains from Investment Securities jumped 1114.81% in 2025, then sank 4032.0% in 2026.
- Galectin Therapeutics' Gains from Investment Securities stood at -$277000.0 in 2022, then decreased by 21.66% to -$337000.0 in 2023, then plunged by 523.74% to -$2.1 million in 2024, then jumped by 110.47% to $220000.0 in 2025, then tumbled by 546.82% to -$983000.0 in 2026.
- Business Quant data shows GALT's Gains from Investment Securities at -$983000.0 in Q1 2026, $220000.0 in Q4 2025, and $2.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Galectin Therapeutics | 304.34 Mn | 304.34 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.16 Mn |
| Mar 31, 2026 | -983,000.00 |
| Dec 31, 2025 | 220,000.00 |
| Sep 30, 2025 | 2.21 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 25,000.00 |
| Dec 31, 2024 | -2.10 Mn |
| Sep 30, 2024 | 754,000.00 |
| Jun 30, 2024 | -108,000.00 |
| Mar 31, 2024 | 868,000.00 |
| Dec 31, 2023 | -337,000.00 |
| Sep 30, 2023 | 490,000.00 |
| Jun 30, 2023 | -490,000.00 |
| Mar 31, 2023 | 769,000.00 |
| Dec 31, 2022 | -277,000.00 |
| Sep 30, 2022 | 224,000.00 |
| Jun 30, 2022 | -275,000.00 |
| Mar 31, 2022 | -229,000.00 |
| Dec 31, 2021 | -476,000.00 |
| Sep 30, 2021 | 166,000.00 |